Merus, which is developing bispecific antibody treatments for solid tumors, announced terms for its IPO on Monday.
The Utrecht, Netherlands-based company plans to raise $65 million by offering 4.3 million shares at a price range of $14 to $16. Insiders intend to purchase $33 million worth of shares in the offering. At the midpoint of the proposed range, Merus would command a fully diluted market value of $223 million.
Merus was founded in 2003. It plans to list on the Nasdaq under the symbol MRUS. Citi and Jefferies are the joint bookrunners on the deal. It is expected to price during the week of May 16, 2016.
